Compare KMDA & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMDA | MRVI |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 458.6M | 472.8M |
| IPO Year | 2013 | 2020 |
| Metric | KMDA | MRVI |
|---|---|---|
| Price | $8.88 | $3.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $13.00 | $4.57 |
| AVG Volume (30 Days) | 65.5K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-26-2026 |
| Dividend Yield | ★ 2.21% | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $185,743,000.00 |
| Revenue This Year | $14.79 | $11.80 |
| Revenue Next Year | $11.38 | $7.74 |
| P/E Ratio | $24.59 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.54 | $1.67 |
| 52 Week High | $9.35 | $4.11 |
| Indicator | KMDA | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 56.02 | 54.74 |
| Support Level | $6.69 | $3.25 |
| Resistance Level | $9.35 | $3.65 |
| Average True Range (ATR) | 0.27 | 0.18 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 60.00 | 63.11 |
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.